USFDA12 Apr 2024, 12:55 am
US FDA Grants Official Action Indicated (OAI) Status to Sun Pharma's Dadra Facility
AI Summary
Sun Pharmaceutical Industries Limited recently received an Official Action Indicated (OAI) status from the US Food and Drug Administration (FDA) following an inspection at their Dadra facility from December 4 to December 15, 2023. The company intends to collaborate with the regulator to rectify any identified issues and achieve fully compliant status.
Key Highlights
- Sun Pharma's Dadra facility receives Official Action Indicated (OAI) status from the US FDA
- The inspection took place between December 4 and December 15, 2023
- The company aims to work with the FDA to rectify any issues and achieve fully compliant status